Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-05-30

Clinical Trial Update: AGN-199201 for the Treatment of Erythema With Rosacea [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for AGN-199201 in erythema associated with rosacea has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AGN-199201

Snippet

Sponsor: Allergan | Conditions: Rosacea, Erythema | Phase 2 | Status: COMPLETED | Results posted: 2014-05-30